Yuhan Corporation

🇰🇷South Korea

Country: 🇰🇷South Korea

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Comparative Pharmacokinetics of YH14659 in Healthy Male Subjects

Phase 1

Completed

Conditions: Acute Coronary Syndrome

Interventions: Drug: YH14659
Drug: clopidogrel & aspirin

First Posted Date: 2012-08-03

Last Posted Date: 2012-08-03

Lead Sponsor: Yuhan Corporation

Target Recruit Count: 60

Registration Number: NCT01657071

Locations: 🇰🇷
Yuhan Corporation, Seoul, Korea, Republic of

Pharmacokinetic Drug Interaction Between Rosuvastatin and Valsartan

Phase 1

Completed

Conditions: Hypertension
Hyperlipidemia

Interventions: Drug: Rosuvastatin+Valsartan (Sequence 1)
Drug: Rosuvastatin+Valsartan (Sequence 2)
Drug: Rosuvastatin+Valsartan (Sequence 3)
Drug: Rosuvastatin+Valsartan (Sequence 4)
Drug: Rosuvastatin+Valsartan (Sequence 5)
Drug: Rosuvastatin+Valsartan (Sequence 6)

First Posted Date: 2012-06-01

Last Posted Date: 2012-06-01

Lead Sponsor: Yuhan Corporation

Target Recruit Count: 30

Registration Number: NCT01609907

Locations: 🇰🇷
Yuhan Corporation, Seoul, Korea, Republic of

Study to Investigate the Safety, Tolerability and Efficacy of YH4808 in Patients With Reflux Esophagitis

Phase 2

Completed

Conditions: Reflux Esophagitis

Interventions: Drug: YH4808 B mg
Drug: YH4808 A mg
Drug: YH4808 C mg
Drug: Esomeprazole 40mg

First Posted Date: 2012-02-24

Last Posted Date: 2014-07-10

Lead Sponsor: Yuhan Corporation

Target Recruit Count: 154

Registration Number: NCT01538849

Locations: 🇰🇷
Seoul ST.MARY'S HOSPITAL, Seoul, Korea, Republic of

A Phase 1 Clinical Trial to Investigate Pharmacokinetics and Drug Interaction of Crestor and Glucodown OR SR in Healthy Volunteers

Phase 1

Completed

Conditions: Pharmacokinetics and Drug Interaction of Crestor and Glucodown SR

Interventions: Drug: Crestor 10mg(Rosuvastatin 10mg), Glucodown OR SR 750mg(Metformin SR 750mg)

First Posted Date: 2012-02-03

Last Posted Date: 2012-08-01

Lead Sponsor: Yuhan Corporation

Target Recruit Count: 36

Registration Number: NCT01526317

Locations: 🇰🇷
Severance Hospital, Yonsei University, Seoul, Korea, Republic of

Safety, Tolerability and Efficacy of YH14618 in Patients With Degenerative Disc Disease

Phase 1

Completed

Conditions: Degenerative Disc Disease

Interventions: Drug: Placebo
Drug: YH14618

First Posted Date: 2012-02-03

Last Posted Date: 2015-05-29

Lead Sponsor: Yuhan Corporation

Target Recruit Count: 48

Registration Number: NCT01526330

Locations: 🇰🇷
Kangbuk Samsung Medical Center, Seoul, Korea, Republic of

Phase I Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of YHB1411-2 in Healthy Male Volunteers

Phase 1

Completed

Conditions: Rheumatic Arthritis

Interventions: Biological: Placebo

First Posted Date: 2012-02-02

Last Posted Date: 2014-07-10

Lead Sponsor: Yuhan Corporation

Target Recruit Count: 49

Registration Number: NCT01525147

Locations: 🇰🇷
Samsung Medical Center, Seoul, Irwon-dong, Gangnam-gu, Korea, Republic of

Food Effect on Pharmacokinetics of YH4808 in Healthy Male Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: YH4808 100 mg
Drug: YH4808 300 mg

First Posted Date: 2012-01-27

Last Posted Date: 2012-07-24

Lead Sponsor: Yuhan Corporation

Target Recruit Count: 44

Registration Number: NCT01520012

Locations: 🇰🇷
Yuhan Corporation, Seoul, Korea, Republic of

Safety and Efficacy of YH14617 in Diabetes Mellitus

Phase 2

Completed

Conditions: Diabetes Mellitus

Interventions: Drug: Placebo
Drug: YH14617

First Posted Date: 2012-01-10

Last Posted Date: 2015-02-18

Lead Sponsor: Yuhan Corporation

Target Recruit Count: 84

Registration Number: NCT01507038

Locations: 🇰🇷
Yuhan, Seoul, Korea, Republic of

A Clinical Trial of YH14642 in Patients With Chronic Periodontal Disease

Phase 2

Completed

Conditions: Chronic Periodontitis

Interventions: Drug: YH14642 500mg Tab
Drug: Placebo
Drug: INSADOL[Zea mays L. extract] 35mg Tab
Drug: DENTISTA[Doxycycline hyclate] 20mg Cap

First Posted Date: 2011-12-26

Last Posted Date: 2014-07-31

Lead Sponsor: Yuhan Corporation

Target Recruit Count: 162

Registration Number: NCT01499225

Locations: 🇰🇷
Seoul National University Dental Hospital, Seoul, Korea, Republic of

Safety and Efficacy of YHD001 in Asthma

Phase 2

Completed

Conditions: Asthma

Interventions: Drug: YHD001 dose level 1
Drug: Singulair
Drug: Placebo
Drug: YHD001 dose level 2

First Posted Date: 2011-08-26

Last Posted Date: 2014-07-10

Lead Sponsor: Yuhan Corporation

Target Recruit Count: 56

Registration Number: NCT01424124

Locations: 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy